On Monday, November 13th, The Life Raft Group in collaboration with Deciphera Pharmaceuticals hosted a webcast which provided patients with an overview of the DCC-2618 GIST program, including enrollment updates from the ongoing phase 1 trial, reviewed key clinical data and provided details on the upcoming Phase 3 registration trial for the treatment of patients who have received at least 3 prior therapies. The webcast closed with a Q&A session.
Oliver Rosen, MD, Chief Medical Officer and Jama Pitman, VP Regulatory Affairs and Quality, both of Deciphera Pharmaceuticals, presented.
Oliver Rosen, MD |
Jama Pitman |
